Claims
- 1. An oral vaccine for preventing or treating rabies in a mammal comprising a hybrid vaccinia virus that contains and expresses a DNA sequence encoding the amino acid sequence rabies glycoprotein G wherein said DNA sequence is present in a non-essential segment of vaccinia virus and a pharmaceutically acceptable carrier.
- 2. The vaccine according to claim 1 wherein said hybrid vaccinia virus is live.
- 3. The vaccine according to claim 1, wherein said rabies glycoprotein G has the first 8 N-terminal amino acids of SEQ ID NO: 1 wherein the amino acid at position 8 has been mutated from Leu to Pro.
- 4. The vaccine according to claim 3, wherein said hybrid vaccinia virus is live.
- 5. The vaccine according to claim 3, wherein said rabies glycoprotein G has the amino acid sequence as depicted in FIG. 1a-b (SEQ ID NO.: 1) starting from Lysine in position 1 and replacing the Leucine residue in position 8 with a Proline residue.
- 6. The vaccine according to claim 3, wherein said rabies glycoprotein G is under the control of the 7.5K vaccinia promoter and is present in the vaccinia thymidine kinase gene.
- 7. The vaccine according to claim 1, wherein said hybrid vaccinia virus is temperature sensitive.
- 8. The vaccine according to claim 1, wherein said DNA sequence is present in a vaccinia thymidine kinase gene.
- 9. The vaccine according to claim 1, wherein said rabies glycoprotein G DNA sequence is under the control of a vaccinia promoter.
- 10. The vaccine according to claim 9, wherein said rabies glycoprotein G DNA sequence is under the control of a 7.5K vaccinia virus promoter.
- 11. The vaccine according to claim 1, wherein said rabies glycoprotein G DNA sequence codes for the complete mature protein.
- 12. The vaccine according to claim 1, wherein said rabies glycoprotein G is preceded by a signal sequence as depicted in FIG. 1a-b (SEQ ID No.: 1) from position -19 to -1.
- 13. The vaccine according to claim 1, wherein said hybrid vaccinia virus is temperature sensitive.
- 14. A method of preventing or treating rabies in a mammal comprising orally administering to said mammal a hybrid vaccinia virus that contains and expresses a DNA sequence encoding rabies glycoprotein G wherein said DNA sequence is present in a non-essential segment of vaccinia virus, in an amount sufficient to prevent or treat rabies.
- 15. The method of preventing rabies according to claim 14, wherein said rabies glycoprotein G has the first 8 N-terminal acids of SEQ ID NO: 1 wherein the amino acid at position 8 has been mutated from Leu to Pro.
- 16. The method of preventing or treating rabies according to claim 15, wherein said rabies glycoprotein G has the amino acid sequence as depicted in FIG. 1 a-b (SEQ ID NO.: 1) starting from Lysine in position 1 and replacing the Leucine residue in position 8 with a Proline residue.
- 17. The method of preventing or treating rabies according to claim 15, wherein said rabies glycoprotein G is under the control of the 7.5K vaccinia promoter and is present in the vaccinia thymidine kinase gene.
- 18. The method of preventing or treating rabies according to claim 14, wherein said DNA sequence is present in a vaccinia thymidine kinase.
- 19. The method of preventing or treating rabies according to claim 14, wherein said rabies glycoprotein G sequence is under the control of a vaccinia promoter.
- 20. The method of preventing or treating rabies according to claim 19, wherein said rabies glycoprotein G DNA sequence is under the control of a 7.5K vaccinia virus promoter.
- 21. The method of preventing or treating rabies according to claim 14, wherein said rabies glycoprotein G DNA sequence codes for the complete mature protein.
- 22. The method of preventing or treating rabies according to claim 14, wherein said rabies glycoprotein G is preceded by a signal sequence as depicted in FIG. 1a-b (SEQ ID NO.: 1) from position -19 to -1.
- 23. The method preventing or treating rabies according to claim 14, wherein said hybrid vaccinia virus is temperature sensitive.
- 24. The method of preventing or treating rabies according to claim 14, wherein said hybrid vaccinia virus is live.
- 25. The method of preventing or treating rabies according to claim 14, wherein said hybrid vaccinia virus is inactivated.
- 26. A method for preventing or treating rabies in a mammal comprising the steps of:
- a) preparing a hybrid vaccinia virus containing and expressing a DNA sequence encoding the amino acid sequence of rabies glycoprotein G, wherein said DNA sequence is inserted within a non-essential region of said vaccinia virus; and
- b) orally administering said hybrid vaccinia virus to said mammal in an amount sufficient to prevent rabies.
- 27. The method for preventing or treating rabies according to claim 26, wherein said hybrid vaccinia virus is administered to said mammal as a pharmaceutical product having a preventive activity against rabies.
- 28. The method for preventing or treating rabies according to claim 26, wherein said pharmaceutical product contains a pharmaceutically acceptable vehicle.
- 29. The method for preventing or treating rabies according to claim 26, wherein said mammal is a fox.
- 30. The method for preventing or treating rabies according to claim 26, wherein said virus is temperature sensitive.
- 31. The method for preventing or treating rabies according to claim 26, wherein said rabies glycoprotein G has the first 8 N-terminal amino acids of SEQ ID NO: 1 wherein the amino acid at position 8 has been mutated from Leu to Pro.
- 32. The method for preventing rabies according to claim 26, wherein said hybrid vaccinia virus is live.
- 33. The method for preventing or treating rabies according to claim 26, wherein said DNA sequence is present in a vaccinia thymidine kinase gene.
- 34. The method for preventing or treating rabies according to claim 26, wherein said rabies glycoprotein G DNA sequence is under the control of a 7.5K vaccinia virus promoter.
- 35. The method for preventing or treating rabies according to claim 26, wherein said amino acid sequence of rabies glycoprotein G is depicted in FIG. 1a-b (SEQ ID NO.: 1) starting from Lysine residue in position 1 and replacing the Leucine residue in position 8 with a Proline residue, and wherein said 7.5K vaccinia virus promotor is placed upstream of the DNA sequence.
- 36. The method for preventing or treating rabies according to claim 35, wherein said amino acid sequence is preceded by a signal sequence as depicted in FIG. 1a-b (SEQ ID NO.: 1) from position -19 to -1.
Priority Claims (1)
Number |
Date |
Country |
Kind |
84 06499 |
Apr 1984 |
FRX |
|
Parent Case Info
This application is a continuation of application Ser. No. 8/231,457, filed Apr. 21, 1994 which is a continuation of application Ser. No. 08/038,052, filed Mar. 29, 1993, now abandoned: which is a continuation of application Ser. No. 07/759,138, filed Sep. 11, 1991, now abandoned; which is a continuation of application Ser. No. 07/378,801, filed Jul. 11, 1998, now abandoned; and which is a continuation in part of application Ser. No. 06/829,144, filed Dec. 24, 1985, now abandoned.
US Referenced Citations (2)
Number |
Name |
Date |
Kind |
4393201 |
Curtis et al. |
Jul 1983 |
|
4722818 |
Paoletti et al. |
Feb 1988 |
|
Foreign Referenced Citations (1)
Number |
Date |
Country |
2526661 |
May 1982 |
EPX |
Continuations (4)
|
Number |
Date |
Country |
Parent |
231457 |
Apr 1994 |
|
Parent |
38052 |
Mar 1993 |
|
Parent |
759138 |
Sep 1991 |
|
Parent |
378801 |
Jul 1989 |
|
Continuation in Parts (1)
|
Number |
Date |
Country |
Parent |
829144 |
Dec 1985 |
|